Answers are grounded in this paper and cite their sources.
The evaluation of prostate cancer risk should be focused on the detection of clinically significant prostate cancer (Grade Group 2 or higher [GG2+]). The use of laboratory biomarkers, prostate MRI, and biopsy techniques described herein may improve detection and safety when a prostate biopsy is deemed necessary following prostate cancer screening.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: